Current approaches to medullary thyroid carcinoma, sporadic and familial

Journal of Surgical Oncology

Volumn 94, Issue 8, 2006, Pages 737-747

  Fialkowski, Elizabeth A ^a   Moley, Jeffrey F ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Campus Box 8109 ^*  (United States)

Author keywords

Chemotherapy; MTC; Multiple endocrine neoplasia; RET tyrosine kinase; Thyroid cancer

Indexed keywords

17 ALLYLAMINOGELDANAMYCIN; ANTINEOPLASTIC AGENT; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; IMATINIB; IODINE 131; LABETUZUMAB; PROTEIN RET; PROTEIN TYROSINE KINASE INHIBITOR; VANDETANIB;

CANCER CLASSIFICATION; CANCER INVASION; DRUG EFFICACY; EARLY DIAGNOSIS; EXTERNAL BEAM RADIOTHERAPY; FAMILIAL THYROID MEDULLARY CARCINOMA; GENE MUTATION; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; METASTASIS INHIBITION; PRIORITY JOURNAL; PROTEIN TARGETING; RADIOIODINATION; RARE DISEASE; REVIEW; SPORADIC THYROID MEDULLARY CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PARAFOLLICULAR CELL; THYROIDECTOMY;

CARCINOMA, MEDULLARY; COMBINED MODALITY THERAPY; GENOTYPE; GERM-LINE MUTATION; HUMANS; LYMPHATIC METASTASIS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B; MUTATION; NECK DISSECTION; PHENOTYPE; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-RET; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 33845420535     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.20690     Document Type: Review

References (53)

1. Cameron JL (ed): Current surgical therapy. Philadelphia: Elsevier Mosby, 2004.
2. Ogilvie JB, Kebebew E: Indication and timing of thyroid surgery for patients with hereditary medullary thyroid cancer syndromes. J Natl Compr Canc Netw 2006;4:139-147.
3. Guillem JG, et al.: ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes (Article in Press).
4. Chi DD, Moley JF: Medullary thyroid carcinoma: Genetic advances, treatment recommendations, and the approach to the patient with persistent hypercalcitoninemia. Surg Oncol Clin N Am 1998;7:681-706.
5. Kaserer K, Scheuba C, Neuhold N, et al.: Sporadic versus familial medullary thyroid microcarcinoma: A histopathologic study of 50 consecutive patients. Am J Surg Pathol 2001;25:1245-1251.
6. Block MA, Jackson CE, Greenawald KA, et al.: Clinical characteristics distinguishing hereditary from sporadic medullary thyroid carcinoma. Treatment implications. Arch Surg 1980;115:142-148.
7. Liska J, Altanerova V, Galbavy S, et al.: Thyroid tumors: Histological classification and genetic factors involved in the development of thyroid cancer. Endocr Regul 2005;39:73-83.
8. Moley JF, DeBenedetti MK. Patterns of nodal metastases in palpable medullary thyroid carcinoma: Recommendations for extent of node dissection. Ann Surg 1999;229:880-887; discussion 887-888.
9. Musholt TJ, Moley JF: Management of persistent or recurrent medullary thyroid carcinoma. Prob Gen Surg 1997;14:89-109.
10. Tung WS, Vesely TM, Moley JF: Laparoscopic detection of hepatic metastases in patients with residual or recurrent medullary thyroid cancer. Surgery 1995;118:1024-1029; discussion 1029-1030.
11. Quayle FJ, Moley JF. Medullary thyroid carcinoma: Including MEN 2A and MEN 2B syndromes. J Surg Oncol 2005;89:122-129.
12. Cohen MS, Moley JF. Surgical treatment of medullary thyroid carcinoma. J Intern Med 2003;253:616-626.
13. Howe JR, Norton JA, Wells SA Jr.: Prevalence of pheochromocytoma and hyperparathyroidism in multiple endocrine neoplasia type 2A: Results of long-term follow-up. Surgery 1993;114:1070-1077.
14. Brandi ML, Gagel RF, Angeli A, et al.: Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001;86:5658-5671.
15. Kouvaraki MA, Shapiro SE, Perrier ND, et al.: RET protooncogene: A review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 2005;15:531-544.
16. Hubner RA, Houlston RS: Molecular advances in medullary thyroid cancer diagnostics. Clin Chim Acta 2006; [Epub ahead of print]
17. Jain S, Watson MA, DeBenedetti MK, et al.: Expression profiles provide insights into early malignant potential and skeletal abnormalities in multiple endocrine neoplasia type 2B syndrome tumors. Cancer Res 2004;64:3907-3913.
18. Carlomagno F, Salvatore G, Cirafici AM, et al.: The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype. Cancer Res 1997;57:391-395.
19. Yip L, Cote GJ, Shapiro SE, et al.: Multiple endocrine neoplasia type 2: Evaluation of the genotype-phenotype relationship. Arch Surg 2003;138:409-416 ; discussion 416.
20. Marsh DJ, Learoyd DL, Andrew SD, et al.: Somatic mutations in the RET proto- oncogene in sporadic medullary thyroid carcinoma. Clin Endocrinol (Oxf) 1996;44:249-2457.
21. Cho NH, Lee HW, Lim SY, et al.: Genetic aberrance of sporadic MEN 2A component tumours: Analysis of RET. Pathology 2005; 37:10-13.
22. Dralle H: Lymph node dissection and medullary thyroid carcinoma. Br J Surg 2002;89:1073-1075.
23. Moley JF, Dilley WG, DeBenedetti MK: Improved results of cervical reoperation for medullary thyroid carcinoma. Ann Surg 1997;225:734-740 ; discussion 740-743.
24. Quayle FJ, Moley JF: Medullary thyroid carcinoma: Management of lymph node metastases. Curr Treat Options Oncol 2005;6: 347-354.
25. Decker RA, Geiger JD, Cox CE, et al.: Prophylactic surgery for multiple endocrine neoplasia type IIa after genetic diagnosis: Is parathyroid transplantation indicated? World J Surg 1996;20:814-820 ; discussion 820-821.
26. Hundahl SA, Cady B, Cunningham MP, et al.: Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the united states during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study. Cancer 2000;89:202-217.
27. Rosato L, Avenia N, Bernante P, et al.: Complications of thyroid surgery: Analysis of a multicentric study on 14,934 patients operated on in Italy over 5 years. World J Surg 2004;28:271-276. Epub 2004 Feb 17.
28. Machens A, Niccoli-Sire P, Hoegel J, et al.: Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 2003;349:1517-1525.
29. Niccoli-Sire P, Murat A, Baudin E, et al.: Early or prophylactic thyroidectomy in MEN 2/FMTC gene carriers: Results in 71 thyroidectomized patients. The French Calcitonin Tumours Study Group (GETC). Eur J Endocrinol 1999;141:468-474.
30. Skinner MA, Moley JA, Dilley WG, et al.: Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med 2005;353:1105-1113.
31. Fugazzola L, Pinchera A, Luchetti F, et al.: Disappearance rate of serum calcitonin after total thyroidectomy for medullary thyroid carcinoma. Int J Biol Markers 1994;9:21-24.
32. Miyauchi A, Matsuzuka F, Hirai K, et al.: Prospective trial of unilateral surgery for nonhereditary medullary thyroid carcinoma in patients without germline RET mutations. World J Surg 2002;26:1023-1028. Epub 2002 May 21.
33. Stepanas A, Samaan N, Hill C, et al.: Medullary thyroid carcinoma: Importance of serial calcitonin measurement. Cancer 1979;43:825.
34. Diehl M, Risse JH, Brandt-Mainz K, et al.: Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: Results of a multicentre study. Eur J Nucl Med 2001;28:1671-1676.
35. Kebebew E, Kikuchi S, Duh QY, et al.: Long-term results of reoperation and localizing studies in patients with persistent or recurrent medullary thyroid cancer. Arch Surg 2000;135:895-901.
36. Tisell LE, Hansson G, Jansson S, et al.: Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. Surgery 1986;99:60-66.
37. Moley JF, Lairmore TC, Doherty GM, et al.: Preservation of the recurrent laryngeal nerves in thyroid and parathyroid reoperations. Surgery 1999;126:673-677; discussion 677-679.
38. Chen H, Roberts JR, Ball DW, et al.: Effective long-term palliation of symptomatic, incurable metastatic medullary thyroid cancer by operative resection. Ann Surg 1998;227:887-895.
39. Saad MF, Guido JJ, Samaan NA: Radioactive iodine in the treatment of medullary carcinoma of the thyroid. J Clin Endocrinol Metab 1983;57:124-128.
40. Brierley J, Tsang R, Simpson WJ, et al.: Medullary thyroid cancer: Analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid 1996;6:305-310.
41. Scherubl H, Raue F, Ziegler R: Combination chemotherapy of advanced medullary and differentiated thyroid cancer. Phase II study. J Cancer Res Clin Oncol 1990;116:21-23.
42. Wu LT, Averbuch SD, Ball DW, et al.: Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine. Cancer 1994;73:432-436.
43. Petursson SR: Metastatic medullary thyroid carcinoma. Complete response to combination chemotherapy with dacarbazine and 5-fluorouracil. Cancer 1988;62:1899-1903.
44. Stein R, Goldenberg DM: A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy. Mol Cancer Ther 2004;3:1559-1564.
45. Sharkey RM, Hajjar G, Yeldell D, et al.: A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer. J Nucl Med 2005;46:620-633.
46. Cohen MS, Hussain HB, Moley JF: Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors. Surgery 2002;132:960-966; discussion 966-967.
47. de Groot JW, Plaza Menacho I, Schepers H, et al.: Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations. Surgery 2006;139:806-814.
48. Ryan AJ, Wedge SR: ZD6474 - A novel inhibitor of VEGFR and EGFR tyrosine kinase activity. Br J Cancer 2005;92:S6-S13.
49. Georgakis GV, Younes A: Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond. Future Oncol 2005;1:273-281.
50. Clark JR, Fridman TR, Odell MJ, et al.: Prognostic variables and calcitonin in medullary thyroid cancer. Laryngoscope 2005;115:1445-1450.
51. Dralle H, Gimm O, Simon D, et al.: Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian experience. World J Surg 1998;22:744-750 ; discussion 750-751.
52. Ukkat J, Lorenz K, Hinze R, et al.: Importance of early screening and prophylactic thyroidectomy in asymptomatic nonindex RET germline carriers. World J Surg 2001;25:713-717.
53. Rodriguez GJ, Balsalobre MD, Pomares F, et al.: Prophylactic thyroidectomy in MEN 2A syndrome: Experience in a single center. J Am Coll Surg 2002;195:159-166.